BARCELONA, Spain — For more than a decade, the standard clinical management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis relied almost exclusively on two antifibrotic medications: pirfenidone and nintedanib. These antifibrotic therapies slow disease progression, but don’t stop it. Now, with a wave of novel therapeutic agents targeting distinct biological pathways entering phase …
Read More
Experts Debate Combination Therapy for Pulmonary Fibrosis
